GlassScriptPhysician profile
Sandra A Rivard
NPI 1023072618
$1,280.19
in general payments reported to CMS, 2019-2025
20 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $112 · 2021: $290 · 2022: $229 · 2023: $82.34 · 2024: $233 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $567.20 | 2019-2023 | Orilissa |
| Sumitomo Pharma America, INC. | $75.21 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $61.01 | 2024-2025 | Solosec, Phexx, Phexxi |
| Pfizer INC. | $59.19 | 2022-2024 | |
| Shield Therapeutics INC | $50.18 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $50.05 | 2020-2025 | |
| Minerva Surgical, INC | $49.43 | 2019 | |
| Avion Pharmaceuticals | $48.88 | 2021-2022 | |
| Hologic Sales and Service, LLC | $45.67 | 2022-2024 | Novasure |
| Allergan, INC. | $43.91 | 2019 | |
| Roche Diagnostics Corporation | $38.95 | 2019 | |
| Novo Nordisk INC | $33.42 | 2019-2024 | Wegovy |
| Mayne Pharma Commercial LLC | $29.97 | 2024-2025 | |
| Astellas Pharma US INC | $29.39 | 2023-2024 | Veozah |
| Daiichi Sankyo INC. | $27.09 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $25.87 | 2019-2020 | |
| Exact Sciences Corporation | $16.97 | 2025 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $14.38 | 2022 | |
| Exeltis, USA INC. | $13.42 | 2024 | Slynd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rivard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.